Search results
Results from the WOW.Com Content Network
EzriCare Artificial Tears Lubricant Eye Drops: According to the CDC, this product was implicated as a common factor in 37 of the 68 logged cases so far. Potentially tainted eye drops can be ...
The bacteria linked to recalled eyedrops causing infection and blindness had never been seen in the U.S. until 2022, the CDC says Almost 70 infections have been linked to the recalled eyedrops in ...
LightEyez MSM Eye Drops-Eye Repair, NDC number not provided. CVS Health Lubricant Eye Drops 15 ml (single pack) , NDC number 76168-702-15. CVS Health Lubricant Eye Drops 15 ml (twin pack) , NDC ...
The 2022–2023 United States Pseudomonas aeruginosa outbreak began in May 2022, with the infection of several patients in California. The Centers for Disease Control and Prevention (CDC) became aware of a strain of Pseudomonas aeruginosa in artificial tears manufactured by EzriCare and Delsam Pharma in January 2023.
Laser blended vision is a laser eye treatment which is used to treat presbyopia (ageing eyes; [1] progressive loss of the ability to focus on nearby objects) or other age-related eye conditions. [1] It can be used to help people that simply need reading glasses, and also those who have started to need bifocal or varifocal spectacle correction ...
In 2021, the U.S. Food and Drug Administration (FDA) approved pilocarpine hydrochloride as an eyedrop treatment for presbyopia, age-related difficulty with near-in vision. It works by causing the pupils to constrict, increasing depth of field , similar to the effect of pinhole glasses .
One lot of eye drops is being voluntarily recalled due to potential fungal contamination, the U.S. Food and Drug Administration announced earlier this week. The eye drops, Systane Lubricant Eye ...
Upon the original patent expiration, Hi-Tech Pharma was the first of many generic competitors to submit an abbreviated new drug application (ANDA) for dorzolamide hydrochloride/timolol maleate eye drops. [19] Hi-Tech Pharma's ANDA was approved on 28 October 2008. At the time, controversy surrounded the approval of this first ANDA.